8月20日，云顶新耀盘中上涨47.06%，报35.14港元，成交额9.8亿港元。
消息面上，8月19日莫德纳与默沙东宣布其合作的mRNA个性化癌症疫苗首个III期临床试验取得初步阳性结果，Moderna隔夜股价飙涨近177%，mRNA赛道迎来价值重估。同日，云顶新耀公布中期业绩，上半年收益11.48亿元，同比增长157.29%，毛利同比增长166.98%，亏损同比大幅收窄97.62%至594.4万元，接近盈亏平衡。营收增长主要受益于核心产品耐赋康持续强劲的销售表现及与海森生物商业化服务协议产生的服务收入。毛利率提升至69.6%。双重利好共振推动股价大幅走高，同板块康希诺生物同日涨43.87%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.